KDR and non-small cell lung carcinoma: NSCLC tumors treated with r84 and bevacizumab showed a reduction in VEGFR2 staining (Figure 4B), with the exception of A549 tumors where bevacizumab had no effect, suggesting specific inhibition of VEGF∶VEGFR2 binding by r84 can down regulate receptor expression.